Canadian court bars Apotex from making generic Plavix

Canada's Apotex is barred from making a generic version of Sanofi-Aventis' blood-thinning drug Plavix, the country's Federal Court has ruled. The ruling, which Apotex said it would appeal, rejected the company's assertion that Sanofi-Aventis' claims for the patent were unjustified, but Plavix still faces a similar challenge in the U.S. Some argue the ruling will help branded drug manufacturers who have seen their financial performance drop in recent years following the introduction of generics.

View Full Article in:

NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI